Voyager Therapeutics (VYGR) announced that Novartis AG (NVS) has agreed to license a novel capsid generated from Voyager’s TRACER capsid discovery platform for use in a gene therapy program against an undisclosed rare neurologic disease target. This capsid license is being granted pursuant to the agreement between Voyager and Novartis originally announced in March 2022. In consideration for the current capsid license, Voyager will receive $15M upfront and is eligible to receive up to $305 million in associated potential development, regulatory, and commercial milestone payments, as well as tiered mid- to high-single digit royalties on a potential product incorporating the licensed capsid for this target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
- Voyager Therapeutics price target lowered to $7 from $8 at Wedbush
- Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
- Voyager Therapeutics reports Q2 EPS (18c), consensus (41c)